David Barr was a contributor to the most recent issue of Reuters Practical Law Journal regarding the U.S. Supreme Court’s grant of certiorari in the Hikma v. Amarin case. The following is an excerpt:
The US Supreme Court recently granted certiorari in a case involving induced patent infringement arising from post-approval marketing of skinny label generic drug products.
Skinny labels under the Hatch-Waxman Act strike a policy balance by permitting generics to avoid patent infringement by omitting still-patented indications from their product labeling when a branded drug has multiple approved uses.
Find a link to the journal here.